December 12, 2025 · Form 4 insider transaction
Shenouda Maged bought 828,000 shares of Relmada Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.